Q2 FY2026 EarningsZBH.US Q2 FY26 beat consensus across the top and bottom lines: net sales reached $2.177B vs. $2.135B expected, with adjusted EPS at $2.07 vs. $2.01 consensus. Growth was driven by robust performance in the 'Technology & Data, Bone Cement and Surgical' segment (+21.5%) and strong U.S. demand. Management raised FY2026 guidance for both organic revenue growth (2.25%-3.25%) and adjusted EPS ($8.47-$8.59), signaling confidence in commercial transformation and innovation momentum.
Financial report interval: 2026.03.30 - 2026.06.30
Overview: Zimmer Biomet(ZBH) the Revenue is 2.177 B (+4.8%), Beat estimate;the EBIT is 559.7 M (-3.25%), Beat estimate;the EPS is 1.03 (+33.77%), Miss estimate.
Actual
YoY
Estimate
YoY
Vs estimate
YoY
RevenueExceed expectations
2.18B4.80%
2.14B2.80%
+0.04B2.00%
EBITExceed expectations
0.56B3.25%
0.55B4.48%
+0.01B1.23%
EPSMiss expectations
1.0333.77%
1.142.86%
-0.07009.09%
Revenue
ActualEstimateUnit: USD
qf
EBIT
ActualEstimateUnit: USD
qf
Net income
ActualEstimateUnit: USD
qf
EPS
ActualEstimateUnit: USD
qf